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Abstract
Background: The virus-specific cytotoxic T lymphocyte (CTL) induction is an important target for the development of a
broadly protective human influenza vaccine, since most CTL epitopes are found on internal viral proteins and relatively
conserved. In this study, the possibility of developing a strain/subtype-independent human influenza vaccine was explored
by taking a bioinformatics approach to establish an immunogenic HLA-A24 restricted CTL epitope screening system in HLA-
transgenic mice.
Methodology/Principal Findings: HLA-A24 restricted CTL epitope peptides derived from internal proteins of the H5N1
highly pathogenic avian influenza A virus were predicted by CTL epitope peptide prediction programs. Of 35 predicted
peptides, six peptides exhibited remarkable cytotoxic activity in vivo. More than half of the mice which were subcutaneously
vaccinated with the three most immunogenic and highly conserved epitopes among three different influenza A virus
subtypes (H1N1, H3N2 and H5N1) survived lethal influenza virus challenge during both effector and memory CTL phases.
Furthermore, mice that were intranasally vaccinated with these peptides remained free of clinical signs after lethal virus
challenge during the effector phase.
Conclusions/Significance: This CTL epitope peptide selection system can be used as an effective tool for the development
of a cross-protective human influenza vaccine. Furthermore this vaccine strategy can be applicable to the development of
all intracellular pathogens vaccines to induce epitope-specific CTL that effectively eliminate infected cells.
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Introduction
Influenza A viruses are highly contagious and cause respiratory
tract infection associated with a marked disease burden. In-
activated influenza A virus vaccines that stimulate the production
of antibodies to surface glycoproteins hemagglutinin (HA) and
neuraminidase (NA) are currently available. The protective role of
antibodies against HA in particular is well established and has
been demonstrated in both infected animals and humans [1].
While the induction of neutralizing antibody production against a
particular viral strain with a matching inactivated vaccine is
generally effective for reducing the intensity of clinical -signs [2],
the effects of these vaccines are limited due to their inability to
stimulate mucosal immunity and cytotoxic T lymphocyte (CTL)
responses, both of which are indispensable for the suppression of
initial viral replication in the respiratory epithelium [3,4].
Furthermore, antibodies induced by inactivated vaccines fail to
protect against infection with different influenza A virus subtypes
or homologous virus strains due to the effect of antigenic drift at
the neutralizing antibody combining site [5].
In contrast to inactivated vaccines, live attenuated influenza
vaccines (LAIV)whichare currentlylicensedintheUnited Statesare
administered intranasally (i.n.) and inducecross-protectiveimmunity
by stimulating mucosal immunity and CTL responses. Clinical
studies indicate that LAIV provide increased protection against
seasonal influenza compared to inactivated vaccines, especially in
young children, even when vaccine strains are sub-optimally
matched to circulating strains [6]. However another report has
suggested that LAIV are not as effective as generally thought,
because protective effect may vary by age and population [7].
Recently, it has been reported that, compared to formalin or
UV inactivated vaccine, gamma irradiated influenza virus provide
significant cross-protection against several virus strains including
highly pathogenic H5N1 subtype [8]. Although LAIV and gamma
irradiated vaccine facilitate cross-protection, the underlying
mechanism of cross-protective immunity and the role of CTLs
in mediating cross-protective immunity remain important areas of
research.
CTLs have been shown to play a significant role in the control
of primary influenza A virus infection in mice [9,10]. Since most
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relatively conserved, CTLs induced by primary infection are able
to contribute to protective immunity against influenza viruses of
various subtypes [11–14]. The protective effect mediated by CTLs
has been confirmed by the adoptive transfer of virus-specific CTLs
that show a protective effect during the course of infection in mice
[15–18] and also by the depletion of CTLs from infected mice
which lead to a more severe disease state and increased mortality
associated with rapid virus replication in the lung [19]. Thus,
cross-protective immunity is mediated at least in part by CTLs
that recognize conserved influenza A virus epitopes [20–22].
Synthetic peptides are the most desirable material for epitope
specific CTL inducing vaccines since they are relatively easy to
produce [23]. Because peptides can be synthesized artificially,
stored lyophilized at room temperature and easily modified with
chemical compounds. However, peptide vaccines have several
disadvantages including the limitations conferred by major
histocompatibility complex (MHC) restriction and poor immuno-
genicity. Firstly, CTLs recognize peptide epitopes presented in a
complex with class I MHC molecules, therefore peptides require
substantial affinity for MHC. Polymorphisms of human leukocyte
antigen (HLA, human MHC) add additional complexity since
peptide epitopes need to be designed with respect to each HLA
haplotype. Several web based prediction programs with modified
algorithms have been designed to predict MHC binding peptides
that are able to cover several major HLA supertypes, thereby
making it possible to narrow down the candidate epitopes which
are able to bind to specific HLA haplotypes [24–27]. HLA-
A*2402 is one of the major HLA supertypes with approximately
60% of the population in Japan being positive for this specific
HLA subtype [28]. Despite being commonly expressed, little is
known about its ability to bind peptides derived from influenza A
virus. Secondly, because CTL responses are difficult to induce
with epitope peptides alone, the addition of an adjuvant or
chemical modification is required for the creation of an effective
peptide vaccine. For example, the addition of potent immune-
enhancing adjuvants such as Poly (I:C) or the toll-like receptor
(TLR) agonist CpG-ODN facilitates the induction of sufficient
CTL responses [29]. In addition, peptide immunogenicity can be
enhanced by cross-linking the N- or C-terminus of the peptide
with carrier molecules such as liposomes. These modifications
allow the delivery of peptide antigens to professional antigen
presenting cells for subsequent enhancement of T cell responses
[30]. Thus, the combination of a carrier conjugated 8–10 mer
peptide and a nucleic acid based adjuvant, such as CpG-ODN,
could make an ideal CTL inducing vaccine.
We reported previously that a liposome conjugated murine class
I MHC restricted NP366–374 peptide epitope derived from the
influenza strain A/Aichi inhibited virus replication in the lung
[29]. Here, we have established a HLA-A*2402 restricted CTL
activating peptide selection system using HLA binding peptide
prediction programs and HLA-A24 transgenic mice to develop a
human influenza peptide vaccine. Peptide epitopes of highly
pathogenic avian influenza A virus proteins were screened and
peptides that induced CTL activity were subjected to a protection
test against different influenza A virus subtypes using a human
CTL immunity mouse model.
Materials and Methods
Viruses
Influenza A virus strains A/HK483 (A/HongKong/483/97
[H5N1]), A/PR8 (A/PuertoRico/8/34 [H1N1]) and A/Aichi (A/
Aichi/2/68/ [H3N2]) were propagated in the allantoic cavity of
10- to 11-day-old embryonated hen’s eggs at 35uC for 48 h. The
amniotic/allantoic fluids were harvested, pooled, and stored at
280uC. Titers were determined using plaque assays on Madin-
Darby canine kidney (MDCK) cells, as described previously [31].
The viruses were kindly provided by Prof. Hiroshi Kida from
Laboratory of Microbiology, Graduate School of Veterinary
Medicine, Hokkaido University (Sapporo, Japan).
Peptides
The 9 mer peptides corresponding to the HLA-A*2402 binders
were predicted by the web-based programs: BIMAS (http://www-
bimas.cit.nih.gov/molbio/hla_bind/), nHLAPred (http://www.
imtech.res.in/raghava/nhlapred/neural.html), SYFPEITHI (http://
www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm)
and NetCTL (http://www.cbs.dtu.dk/services/NetCTL/). Predict-
ed putative CTL epitope peptides derived from internal proteins of
influenza virus A/HK483 were manufactured, HPLC purified
(.90% purity), and analyzed by mass spectrometry (Invitrogen,
Carlsbad, CA). The peptides were dissolved in dH2O at 1.0 mg/ml
with or without various concentrations of NaHCO3 and stored at
220uC. For carrier-conjugated peptide experiments, liposomes
consisting of dioleoyl phosphatidyl choline, dioleoyl phosphatidyl
ethanolamine, dioleoyl phosphatidyl glycerol acid, and cholesterol
in a 4:3:2:7 molar ratio were provided by Nippon Oil and Fat
Corporation (Tokyo, Japan) and used, as described previously [32].
The crude liposome solution was passed through a membrane filter
(Nucleopore polycarbonate filter, Corning Coster) with a pore size
of 0.2 mm. Liposome conjugated peptides were prepared using
disuccinimidyl suberate (DSS) for cross-linking, as described
previously [33]. These peptide-conjugated liposomes were kindly
prepared by Dr. Uchida at Department of Safety Research on
Blood and Biological Products, National Institute of Infectious
Disease, Tokyo, Japan.
Mice
HLA-A24 transgenic (A24Tg) mice (kindly provided by Dr.
Franc ¸ois Lemonnier, De ´partement d’Immunologie, Institut Pas-
teur, Paris, France) were bred under specific-pathogen-free
conditions. These mice have a C57BL/6 background and express
HLA-A*2402, human ß2 microglobulin and CD8 molecules, but
do not express either murine H2D
b nor H2K
b. All experimental
procedures were approved by Hokkaido University Animal Care
and Use Committee (approval number 10-0060), Sapporo, Japan.
In vivo cytotoxicity assays
Eight to 12 week-old A24Tg mice were immunized subcutane-
ously (s.c.) twice with each liposome-conjugated peptide in the
presence of CpG-ODN (CpG5002, 5 mg/mouse) (Hokkaido
System Science, Sapporo, Japan) or poly(I:C) (10 mg/mouse)
(InvivoGen, San Diego, CA). Splenocytes from A24Tg mice were
suspended in PBS and then labeled with two different concentra-
tions (5 mM or 0.5 mM) of carboxyfluorescein diacetate succini-
midyl ester (CFDA-SE, Invitrogen) at room temperature for
10 min. After addition of equal volumes of heat inactivated rabbit
serum to quench the CFSE labeling reaction, cells were washed
twice with PBS. Cells were further incubated with 0.5 mM
immunizing peptide or an irrelevant peptide for 2 h at 37uC
and 5% CO2. Five million cells cultured with respective peptides
were mixed together and inoculated intravenously (i.v.) into
immunized mice. Eighteen hours after target cells were inoculated,
splenocytes were harvested and ten thousand CFSE-positive cells
were analyzed by flow cytometry with dead cell exclusion
performed by propidium iodide staining (PI, Invitrogen). Peptide
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formula:
ITCR (inoculated target cell ratio)=(number of immunized
peptide pulsed cells harvested from PBS injected mice)/(number of
irrelevant peptide pulsed cells harvested from PBS injected mice),
% specific reduction={(number of irrelevant peptide pulsed cells
harvested from immunized mice)6ITCR2(number of immunized
peptide pulsed cells harvested from immunized mice)}/{(number
of irrelevant peptide pulsed cells harvested from immunized
mice)6ITCR}6100.
Titration of virus
MDCK cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37uC in a humidified atmosphere with 5% CO2.
Suspensions of the lung cells serially diluted 1 in 10 were
inoculated into confluent MDCK cell monolayers on 6-well
plates and incubated at 35uC. After 1 h adsorption, the inoculum
was removed and cells were overlaid with minimal essential
medium (MEM) containing 1% bacto agar (BD Diagnostic
Systems, Sparks, MD) and 5 mg/ml of trypsin (Invitrogen). After
incubation at 35uC for 2 days in 5% CO2, the plaques were
counted. The limit of detection in this assay was 1610
3 PFU/g
[34].
Virus protection tests
Eight to 12 week-old A24Tg mice were immunized s.c. or i.n.
with a mixture of peptide-liposome conjugates and CpG-ODN
(CpG5002, 5 mg/mouse) or poly(I:C) (10 mg/mouse) and were
anesthetized with sodium pentobarbital. The mice were re-
immunized one and two weeks later. Control mice were given
PBS or CpG-ODN under the same conditions. One week after
the final immunization, 3 to 10 mice in each group were
challenged i.n. with 50 mlo f2 0 650% mouse lethal doses
(MLD50) of A/HK483, A/PR8 or 20650% mouse infectious
doses (MID50) of A/Aichi under anesthesia. Five days after the
virus challenge, 4 to 5 mice were sacrificed to obtain tissue
samples. Body weights were observed every day for 14 days after
the challenge. All mice were sacrificed when a body weight loss
percentage of over 25% was reached. The MLD50 and MID50
were determined by infecting 5 mice i.n. with 10 ml of serial 10-
fold dilutions of the viruses.
Immunohistochemistry
Eight to 12 week-old A24Tg mice were vaccinated i.n. with
45 ml of peptide-liposome conjugates in the presence of CpG-
ODN weekly over a period of three weeks. Lungs were harvested
at 7 days after the final immunization, embedded in O.C.T.
compound (Sakura) and slowly frozen in dry ice-2-propanol. Ten
mm thick frozen sections were prepared in a cryostat and air-dried
for 1 hour at room temperature. The sections were post-fixed in
acetone:ethanol (1:1) solution, rehydrated in PBS and incubated in
excess avidin followed by incubation with excess biotin (Avidin/
Biotin Blocking Kit; Vector Laboratories). The sections were
stained with biotinylated hamster anti-mouse CD3 (eBioscience,
San Diego, CA) or biotinylated rat anti-mouse CD8a (R&D
Systems ) antibodies. Immunohistochemical staining was per-
formed using a HistoMouse-Plus Kit (Invitrogen), according to the
manufacturer’s instructions.
Statistical analyses
Statistical analyses were carried out using Student’s t-test. P
values,0.05 were considered significant.
Results
Prediction of HLA-A24 binding epitopes derived from
internal proteins of influenza A virus
While the selective pressure from neutralizing antibodies
induces a high frequency of antigenic drift in influenza A virus
surface proteins, HA and NA , the amino acid sequences of
internal proteins, such as matrix (M), nonstructural (NS),
nucleocapsid (NP), polymerase acidic (PA), polymerase basic
1(PB1) and polymerase basic 2 (PB2), are relatively well-conserved.
To develop a viral subtype-independent vaccine, eight internal
proteins of the influenza A/HK483 strain, including two post-
translational products of both the M and NS genes, were used as
templates for the CTL epitope. A total of 35 epitope candidates
that indicated high scores from the data processed by the HLA-
A24 binding peptide prediction programs, with or without several
options, were initially chosen. All predicted epitope peptides were
synthesized, purified (.90% purity) and used in further experi-
ments.
In vivo validation of immunogenic CTL epitopes using
A24Tg mice
To confirm whether the predicted peptides have sufficient
immunogenicity to induce peptide antigen specific CTL activa-
tion, HLA-A24Tg mice were immunized with liposome-conjugat-
ed peptide weekly over two weeks. In vivo cytotoxicity analysis
showed that 10 peptides induced CTL activity (Table 1).
Among the six peptides that showed high immunogenicity
(more than 50% killing), five peptides were identical between A/
HK483 and A/PR8, and two of these were also identical among
the three viral subtypes including A/Aichi.
To demonstrate the restriction of these peptides to HLA-
A*2402, C57BL/6 mice which were background of A24Tg mice
were immunized with three highly immunogenic HLA-A*2402
restricted peptides and in vivo cytotoxicity assay was performed.
This result showed that the immunogenicity of the peptides were
not provoked by strain background but by transgenic HLA-
A*2402 (Figure S1). Furthermore, we performed HLA stabiliza-
Table 1. Screened immunogenic CTL epitopes by in vivo
cytotoxicity assay using A24Tg mice.
Peptide
A/HK/483/97
(H5N1)
A/PR/8/34
(H1N1)
A/Aichi/2/34
(H3N2) %Killing
b
PA45–53 CFMYSDFHF CFMYSDFHF CFMYSDFHF 59%
PA130–138 YYLEKANKI YYLEKANKI YYLEKANKI 95%
PB1216–224 SYLIRALTL SYLIRALTL GYLIRALTL 22%
PB1430–438 RYTKTTYWW RYTKTTYWW KYTKTTYWW 95%
PB1482–490 SYINRTGTF SYINRTGTF SYINKTGTF 56%
PB1688–696 MYQKCCTLF MYQRCCNLF MYQKCCNLF 89%
PB2117–125 TYFEKVERL TYFERVERL TYFDKVERL 13%
PB2322–330 SFSFGGFTF SFSFGGFTF SFSFGGFTF 38%
PB2549–557 TYQWIIRNW TYQWIIRNW TYQWVIRNW 95%
M240–48 LWILDRLFF LWILDRLFF LWILDRLFF 5%
Tyrosinase206–214
a AFLPWHRLF 96%
aHLA-A*2402 binding high immunogenic peptide, which is unrelated to
influenza virus antigen.
bIn vivo peptide specific cell reduction ratios were calculated using the formula
described in Materials and Methods.
doi:10.1371/journal.pone.0024626.t001
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A*2402 cells) to demonstrate the restriction of the peptides to
HLA-A*2402. The surface expression of HLA-A*2402 on RMA-
S- A*2402 cells was stabilized in a dose-dependent manner when
cells were cultured with three highly immunogenic HLA-A*2402
restricted peptides, whereas the expression was not stabilized when
cells were cultured with irrelevant peptide (Figure S2). Therefore,
the restrictions of highly immunogenic peptides to HLA-A*2402
were confirmed.
Single epitope vaccinated mice exhibited limited
protection against H5N1 virus infection
In order to elucidate the potency of each of the six highly
immunogenic peptides, we examined the protective effect of each
individual peptide against influenza A/HK483 virus infection.
The A24Tg mice were immunized i.n. with each peptide three
times at 7 to 9 day intervals and were then infected with A/
HK483 virus 1 week after the final immunization. Although
unimmunized mice began losing body weight at day 4, mice
immunized with PA130–138, PB1430–438 or PB2549–557 began losing
weight at day 7 or later. Moreover, 25 to 50% of mice that had
been immunized with PA130–138, PB1430–438 or PB2549–557
survived after exposure to a lethal dose of virus and exhibited
milder clinical signs (Figure 1A). To exclude the possibility that
non-specific protection of the irrelevant peptide or CpG-ODN
diminished infectivity, mice were also immunized i.n. with
Tyrosinase206–214 or CpG-ODN plus empty-liposome solution
before being challenged with a lethal dose of A/HK483 virus. In
the result, non-specific protection by Tyrosinase206–214 or CpG-
ODN was not observed (Figure 1A). Moreover non-specific lung
tissue disruption by CpG-ODN administration was also not
observed (Figure S3).
From these results, we hypothesized that reduced mortality rate
and severity of disease correlated with an inhibition of viral
replication in the lung. A comparison of virus titers in the lungs of
immunized and unimmunized mice 5 days after influenza
challenge showed that although the titers in A24Tg mice
immunized with PA130–138 or PB1430–438 decreased with statistical
significance compared to that of unimmunized mice, the titers
were still high to provide complete protection (Figure 1B). The
correlation between immunogenicity and protection was indicated
but the induction of single epitope specific CTL was not sufficient
for protection against lethal influenza A virus infection.
Nasal vaccination with multiple highly immunogenic CTL
epitopes provides complete protection
To enhance the protective effect of the immunogenic peptides,
three peptides (PA130–138, PB1430–438 and PB2549–557) from
different segments of the influenza A virus genome which
displayed the highest killing activity (Table 1) were chosen as
peptide vaccine candidates. As a comparison, other three peptides
set (PA45–53, PB1482–490, PB1688–696) were also chosen.
As previously reported, mucosally induced CTLs mediate
effective protection against mucosal pathogens [35] in the same
way i.n. administered formalin-inactivated virus vaccines effec-
tively elicit broad spectrum humoral immunity [30]. Therefore,
the vaccine efficacy of immunization route was compared.
Mice were vaccinated i.n. or s.c. three times with the mixture of
three peptides, and then challenged 7 to 10 days after the final
immunization with A/HK483 (40 PFU/mouse) or A/PR8
(1,000 PFU/mouse). More than half of the s.c. vaccinated mice
survived after lethal infection with both viral subtypes, however
they showed clinical signs similar to those of unvaccinated mice
until day 8 after viral challenge. In contrast, all mice i.n.
Figure 1. Protective effect of single epitope vaccinated mice is not sufficient against lethal virus challenge. A24Tg mice were
immunized i.n. three times at 7 to 9 days intervals with each peptide in the presence of CpG-ODN, PBS alone or CpG-ODN plus empty-liposome
solution, and then infected i.n. with lethal dose of A/HK483 (H5N1) (40 PFU/mouse) 1 week after the final immunization. The survival and the body
weight were monitored for 14 days (A). On day 5 post-infection, lung viral titers of PA130–138, PB1430–438 or PB2549–557 peptide immunized mice were
determined by calculating TCID50 using MDCK cells as described in Materials and Methods (B). *p,0.05. , **p,0.01.
doi:10.1371/journal.pone.0024626.g001
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557) survived the lethal dose infection, with no body weight loss (A/
HK483 infection) or diminished body weight reduction (A/PR8
infection) observed (Figure 2). On the other hand, mice vaccinated
with another peptide combination (PA45–53, PB1482–490, PB1688–
696) did not survive. This result indicated that mixing of the
peptides, which did not show the protective effect by single peptide
vaccination, did not provide protection against lethal virus
challenge.
Thus, our data demonstrated that i.n. administration of a CTL
inducing peptide vaccine provided enhanced protection compared
to when s.c. immunization was performed. In addition, intranasal
vaccination with multiple epitopes, which showed some survival
protection effect by single peptide vaccination, induced complete
protection against lethal virus challenge.
Early viral clearance in the lung of intranasally vaccinated
mice
Compared to the early onset of clinical signs in s.c. immunized
mice, i.n. immunized mice exhibited a marked reduction in the
severity of clinical signs with delayed manifestation. Therefore we
speculated that i.n. vaccinated mice were able to achieve early
viral clearance in the lung. Following this, i.n. immunized or
unimmunized A24Tg mice were challenged with A/HK483
(40 PFU/mouse), A/PR8 (1,000 PFU/mouse) and A/Aichi
(500 PFU/mouse) respectively and lung viral titers were assessed
5 days after viral challenge. Compared to the unvaccinated
groups, a significant decrease in viral titer was observed in all
vaccinated groups. In particular, the A/HK483 and A/Aichi virus
infected groups showed a reduction of up to 2 logs average viral
titers (Figure 3). These results support the notion that early viral
clearance can be induced by i.n. immunization using a peptide
vaccine.
Intranasal vaccination with immunogenic peptides
induces peribronchiolar recruitment of CD8
+ T cells
To clarify the contribution of CTLs to early viral clearance
induced by i.n. peptide vaccination, we evaluated whether or not
T cells are present in lung tissue at the time point of virus infection.
Mice were vaccinated i.n. or s.c. weekly for three weeks with the
mixture of PA130–138, PB1430–438 and PB2549–557 peptides in the
presence of CpG-ODN, Tyrosinase206–214 plus CpG-ODN or
CpG-ODN plus empty-liposome solution and lungs were
harvested one week after the final immunization. Lungs from
mice i.n. immunized with three peptides or Tyrosinase206–214
showed an accumulation of murine CD3
+ and CD8
+ cells around
the bronchioles. Moreover Gr1 positive cells as inflammatory cells
were also detected in immunized mice lung (data not shown). In
Figure 2. Intranasal vaccination with multiple CTL epitopes provides complete protection against lethal viral challenge. A24Tg mice
were immunized i.n. or s.c. three times at 7 to 9 days intervals with the mixture of PA130–138, PB1430–438 and PB2549–557 peptides or the mixture of
PA45–53, PB1482–490 and PB1688–696 peptides in the presence of CpG-ODN, unimmunized mice were administrated i.n. with PBS alone. Seven to 10 days
after the final immunization, mice were challenged with A/HK483 (H5N1) (40 PFU/mouse) (A) or A/PR8 (H1N1) (1000 PFU/mouse) (B), and the survival
and the body weight were monitored for 14 days.
doi:10.1371/journal.pone.0024626.g002
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+ cell infiltration was observed in the lungs of
mice s.c. immunized with three peptides or i.n. immunized with
CpG-ODN plus empty-liposome solution (Figure 4). Tyrosi-
nase206–214 induced CD8
+ cells around the bronchioles (Figure 4),
but all A24Tg immunized with Tyrosinase206–214 died after lethal
A/HK483 infection (Figure 1A). This result demonstrated that
the presence of effector CD8
+ T cells induced by irrelevant
peptide and the inflammatory milium they create do not provide
protection against viral challenge.
Therefore our data indicates that i.n. inoculation of immuno-
genic peptides induced peribronchiolar T cells infiltration and the
accumulation of T cells induced by immunogenic peptides derived
from influenza virus in lung is required for early viral clearance of
lung.
Efficacy of long-lasting protection against lethal virus
challenge in vaccinated mice
Finally, we evaluated the efficacy of long-lasting protection
induced by peptide vaccine against influenza A virus, which is a
requirement for the practical use of vaccines. A24Tg mice were i.n.
immunized three times with the mixture of PA130–138,P B 1 430–438
and PB2549–557 peptides and then infected with lethal dose of A/
Figure 3. Early viral clearance can be introduced by i.n. immunization using a three peptide combination vaccine. A24Tg mice were
immunized i.n. three times at 7 to 9 days intervals with the mixture of PA130–138, PB1430–438 and PB2549–557 peptides in the presence of CpG-ODN, or
PBS alone. A week after the final immunization, mice were challenged with A/HK483 (40 PFU/mouse), A/PR8 (1000 PFU/mouse) or A/Aichi (500 PFU/
mouse). On day 5 post-infection, lung viral titers were determined by calculating TCID50 using MDCK cells as described in Materials and Methods.
*p,0.05. , **p,0.01.
doi:10.1371/journal.pone.0024626.g003
Figure 4. An accumulation of murine CD3
+ and CD8
+ cells around the bronchioles in intranasally immunized mice. A24Tg mice were
immunized three times at 7 to 9 days intervals i.n.(A,C,D,E) or s.c.(B) with PA130–138, PB1430–438 and PB2549–557 peptides in the presence of CpG-ODN
(B,C,D), Tyrosinase206–214 plus CpG-ODN (E) or CpG-ODN plus empty-liposome solution (A). Lungs were harvested at day 7 after the final
immunization, embedded in O.C.T. compound, frozen in dry ice-2-propanol. Ten mm thick frozen sections were prepared. The sections were post-
fixed in acetone:ethanol (1:1) solution and blocked endogenous avidin and biotin activity, then stained with anti-mouse CD3 (A,B,C) or anti-mouse
CD8a (D,E).
doi:10.1371/journal.pone.0024626.g004
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thefullprotectionofferedduringtheeffectorphase(1to2weeksafter
the final immunization) after vaccination, A24Tg mice immunized
i.n. developed disease indistinguishable from that of unvaccinated
mice eight days after viral infection (Figure 5A). In addition, survival
rates dropped by half compared to those with full protection. The
rates of body weight loss were similar to those of s.c. vaccinated mice
during the effector phase. Therefore, we vaccinated A24Tg mice s.c.
twice with three immunogenic peptides, with additional s.c. or i.n.
vaccination after the final s.c. immunization, and then compared the
protective efficacy of induced memory T cells. Although the
unimmunized mice did not survive, half of the mice that were s.c.
immunized three times and s.c immunized twice with an additional
i.n. booster survived after challenge with a lethal dose of A/HK483
virus (Figure 5B). The difference of protective efficacy by
administration route was not observed in the memory CTL phase.
Discussion
Many vaccination strategies against influenza A virus infection
have demonstrated an ability to elicit virus subtype independent
cross-protective immunity [36–38]. Among these, the use of
peptide-based CTL-inducing vaccines is well established. This
approach has additionally been used to induce cancer immunity in
clinical trials [39,40]. However, the immunogenicity of epitope
peptides has been a long-standing problem, preventing the
induction of a sufficient immune response for infected cell
removal. In this study, an in vivo immunogenic peptide selection
system was used to identify several HLA-A*2402 restricted
immunogenic CTL epitopes derived from internal proteins of
the H5N1 highly pathogenic influenza A strain. We have
previously shown that epitope peptides are able to induce potent
CTL responses after being chemically cross-linked on the surface
of liposomes [29]. In this report, we investigated the effect of
different administration methods on the efficacy of a CTL peptide
vaccine.
Early viral clearance after influenza A virus infection is required
for a significant reduction in the severity of symptoms and the
prevention of lethal viral pneumonia [15,17,18,41,42]. The
findings reported here are in agreement with this concept. All
A24Tg mice survived after a lethal challenge of influenza virus and
avoided body weight loss when viral titers in the lung decreased by
approximately 100-fold after mixed peptide i.n. vaccination. Mice
vaccinated with s.c. showed a delayed protective effect compared
to i.n. vaccination of the same peptide. This suggests that CTLs
induced by s.c. immunization do not destroy the infected airway
epithelial cells immediately, although they are able to kill i.v.
injected target cells effectively.
Figure 5. Maintenance of long-lasting protection against lethal dose challenge in vaccinated mice. A24Tg mice were immunized i.n.
three times (A), s.c. three times or s.c. twice followed by i.n. (B) with PA130–138, PB1430–438 and PB2549–557 peptides at 7 to 9 days intervals,
unimmunized mice were administrated with PBS. Eight weeks after the final immunization, mice were challenged i.n. with lethal dose of A/HK483
virus, and the survival and the body weight were monitored for 14 days.
doi:10.1371/journal.pone.0024626.g005
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the most important factors for facilitating protection against
influenza A virus infection. The presence of CTLs that specifically
recognize virally infected cells is also required in airway tissue for
effective protection.
The contribution of viral antigen specific CTLs in cross-
recognition against influenza A virus has been proven using mouse
models [43,44] and also in human peripheral blood mononuclear
cells [45]. Broadly protective vaccines against influenza A virus
infection require CTL epitope peptides to be conserved and
invariable. Indeed three HLA-A*2402 restricted epitope peptides;
PA130–138, PB1430–438 and PB2549–557, which exhibit potent CTL
activity in vivo are highly conserved among all identified influenza
A virus sequences listed in the influenza sequence database
(http://www.flu.lanl.gov). Although these peptides are highly
immunogenic, vaccination with each of these peptides does not
show a sufficient protective effect against highly pathogenic
influenza A infection. Since the abundance of viral protein
expressed in infected cells is a key for determining the immuno-
dominance of CTL epitopes [46], the ineffectiveness of single
peptide vaccines could be due to the presence of these viral
epitopes, which are abundantly expressed in infected cells. Also,
because the expression levels of each polymerase protein in
infected cells are not comparable to the expression levels of NP
and M1 (matrix protein), it would be expected that partial
activation of polymerase specific CTLs would occur, thereby
preventing early viral clearance.
The ultimate goal of this vaccine is to stimulate memory CTLs
that have the capacity to mediate early influenza A virus
clearance. However, as demonstrated in this report, although
i.n. administration of the peptide vaccine protected half of the
mice from a lethal dose of A/HK483 virus, a reduction in body
weight was still observed (Figure 5A). This pattern of protection is
similar to that observed in s.c. vaccinated mice which were
infected during the effector CTL phase. This suggests that after
effector CTLs accumulate within the bronchiolar tissue, they do
not remain on-site as memory CTLs after i.n. epitope peptide
inoculation. This notion is consistent with a previous report
showing that peripheral memory T cells of lung are recruited from
the circulation [47].
Several reports indicated that helper T cell assistance is
significant for augmentation of viral antigen specific memory
CTL response and viral clearance [48–50]. Therefore, in
preliminary study, we have tried co-administration of several
reagents those induce or mimic co-stimulation of antigen
presenting cells by activated helper T cells. However, none of
them including influenza virus derived helper T cell epitope
(NP311–325, I-A
b restricted) and stimulatory anti-CD40 antibody
did not show any improvement in both lethal rate and symptom
progression after virus challenge at memory CTL phase in H5N1
virus in vivo protection assay (data not shown). We speculate that
this invalidity of helper T cell help at memory CTL phase may be
relying on property of A24Tg, virulence of H5N1 virus or
immunization method using liposome peptide. In any case, further
refinement of vaccination strategies may be required for their
practical use. For example, annual i.n. vaccination may be
required to recruit influenza antigen specific CTLs into the airway
epithelia since the protection afforded by CTL peptide vaccines
during the effector phase in the lung is more effective than that
during the memory phase.
In conclusion, we have identified potent epitope peptides
which can be used in a cross-protective CTL-inducing human
vaccine against various influenza A virus subtypes using an in
vivo HLA-A*2402 restricted epitope peptide selection system. It
was observed that the efficacy of CTL inducing peptide
vaccines against influenza A virus infection depended largely
on two factors; whether the affinity/avidity of epitope peptides
to the T cell receptor allows the stimulation of large viral
antigen specific CTL populations, and the ability of these
vaccines to recruit specific effector/memory CTLs in the lung.
Therefore CTL peptide vaccines can be further modified to
compensate for the shortcomings (such as virus subtype
dependence, an inability of CTL induction etc.) of existing
influenza vaccines and improve cross-protective responses
against antigenic variants.
Supporting Information
Figure S1 HLA-A*2402 restricted peptides do not induce
epitope specific CTL in C57BL/6 mice. C57BL/6 mice
were immunized s.c. twice with each HLA-A*2402 (human
MHC class I) restricted peptide or H2D
b (C57BL/6 mice MHC
class I) restricted peptide at 7 days interval. Seven days after the
final immunization, bright CFSE-labeled target cells pulsed with
immunized peptide and dim CFSE-labeled target cells pulsed
with irrelevant peptide were injected i.v. as an in vivo CTL killing
assay. Viability of the target cells in the spleen was examined
at 20 h after injection. Epitope specific cell reduction ratios
were calculated using the formula described in Materials and
Methods.
(TIF)
Figure S2 Stabilization assay of the three highly immu-
nogenic peptides to HLA-A*2402. The restriction of PA130–
138, PB1430–438 or PB2549–557 peptides to HLA-A*2402 was
examined by using RMA-S- A*2402 cells. Mean fluorescence
intensity (MFI) was recorded at 1, 10 and 100 mM of peptide. The
stability of HLA-A*2402 was evaluated by the delta percent mean
fluorescence intensity ( MFI %) increase of the HLA-A*2402
detected by staining with anti-HLA-A24 antibody.
(TIF)
Figure S3 Non-specific lung tissue disruption/inflam-
mation by CpG-ODN administration is not observed.
A24Tg mice were immunized i.n. three times at 7 days interval
with PBS alone or CpG-ODN plus empty-liposome solution.
Lungs were harvested at day 7 after the final administration,
preserved in 4% formalin, embedded in O.C.T. compound,
frozen in dry ice-2-propanol, and 5 mm thick frozen sections
were prepared. The sections were stained with Hematoxylin &
Eosin.
(TIF)
File S1 Supplementary Materials and Methods.
(DOC)
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